Literature DB >> 34528166

A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension.

Beatrice Laura Montinaro1,2, Viviana Bozzano1,3, Angelica Carandina1, Giorgio Alberto Croci4,5, Alessio Di Fonzo6,7, Eleonora Tobaldini8,9.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34528166      PMCID: PMC8442640          DOI: 10.1007/s11739-021-02832-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


× No keyword cloud information.

Presentation of case

Dr. Montinaro: a 79-year-old man was admitted to our hospital, because of diarrhoea and pre-renal acute kidney injury AKI. The gastrointestinal syndrome developed 3 days before the admission. The symptoms were not responsive to common antimotility agents, and the patient developed severe fatigue and syncopal prodromes in orthostatism. The patient’s medical history included paucisymptomatic idiopathic pulmonary fibrosis IPF with usual interstitial pneumonia pattern treated with protein-kinase inhibitor Nintedanib, chronic kidney disease, bilateral nephrolithiasis, benign prostatic hyperplasia and previous cholecystectomy. His medical record was also notable for a 2-year history of relapsing episodes of transient loss of consciousness (T-LOC) that did not have specific triggers, such as defecation, cough or sneeze, post-exercise, or emotional triggers. Some episodes lead to falls with severe traumatic outcomes, and in one case, the patient had been hospitalized for post-traumatic subarachnoid haemorrhage and the c5 vertebrae fracture. At that time, sick sinus syndrome was identified, and the patient was implanted with a bicameral pacemaker (DDDR) and discharged with calcium channel blockers. However, runs of sustained atrial tachycardia were seen, and the patient was started on low-dose beta-blockers and anticoagulation with a direct oral anticoagulant. Despite the listed interventions, the patient kept on experiencing severe traumatic falls due to syncopal T-LOC, but pacemaker interrogation did not reveal any further rhythm anomalies. On arrival at the emergency department, the patient was unable to keep the upright position because of asthenia. The axillary temperature was 36 °C, the heart rate (HR) 78 beats per minute (bpm), the blood pressure (BP) in clinostatism was 120/90 mm Hg, and the oxygen saturation 98% while breathing in ambient air. The lungs presented bilateral crackles at the middle and lower fields, which were fibrosis-related findings previously described at pneumological follow-up. The heart was normal on auscultation, with rhythmic heart sounds and without detectable heart murmurs. He had diffused abdominal discomfort with point tenderness on palpation of the left flank, without signs of peritonism. Peripheral pulses were valid and symmetrical, and the skin was normally perfused. Electrocardiography (ECG) showed sinus rhythm at 78 bpm, left anterior fascicular block, and some premature ventricular contractions, and was comparable to previous ECGs. On blood testing, a moderate deterioration in the baseline renal function was noted, with increased levels of serum creatinine and blood urea nitrogen, suggesting a pre-renal origin of AKI. There was a rise in acute phase proteins and international normalized ratio (INR) was prolonged. Serum electrolytes and blood levels of transaminases, alkaline phosphatase, bilirubin, lipase, and complete blood count were normal (Table 1). Urine dipstick was positive for leukocytes, erythrocytes, and protein. Abdominal radiography confirmed the known nephrolithiasis but did not show any remarkable pathological sign. Chest radiography and computed tomography (CT) of the thorax were compared to those acquired ten months before during pneumological follow-up and showed an evolution of the known IPF. Nasopharyngeal swab for SARS-Cov-2 tested negative. Blood, urine, and faeces were obtained for culture, and the patient was started on empirical antimicrobial therapy with Ceftriaxone and volume support with Lactated Ringer’s solution.
Table 1

Laboratory data upon arrival and at discharge from hospital

VariableReference range, adultsOn arrivalAt discharge
Hemoglobin (g/dl)13.5–17.512.311.1
Hematocrit (%)41.0–53.03733.5
Mean corpuscular volume (fl)80.0–94.092.592.5
White-cell count (per μl)4800–10,80086905900
Differential count (%)
 Neutrophils40.0–70.053.266.7
 Lymphocytes22.0–44.02.819.5
 Monocytes4.0–11.012.09.7
 Eosinophils0.0–8.02.13.6
Platelet count (per μl)130,000–400,000205,000194,000
Sodium (mmol/l)135–145145139
Potassium (mmol/l)3.3–5.14.84.6
Chloride (mmol/l)96–108108
Calcium (mg/dl)8.40–10.208.70
Magnesium (mg/dl)1.73–2.262.24
Urea nitrogen (mg/dl)15–5012157
Creatinine (mg/dl)0.72–1.183.181.81
Lactate (mmol/l)0.5–2.01.1
Glucose (mg/dl)70–110102
Alanine aminotransferase (IU/l)9–5948
Aspartate aminotransferase (IU/l)10–3593
γ-glutamiltransferase (IU/l)8–6137
Alkaline phosphatase (IU/l)40–12973
Bilirubin (total) (mg/dl)0.12–1.100.39
Lipase (UI/l)13.0–60.045
Albumin (g/dl)3.4–4.83.4
Creatine kinase (IU/l)38–174203
Lactate dehydrogenase (IU/l)135–225335
C-reactive protein (mg/dl) < 0.58.77
International normalized ratio0.84–1.201.72
APTT ratio0.86–1.201.01
Folate (μg/l)4.6–18.72.5
Vitamin B12 (ng/l)191–663384
Serum iron (μg/dl)59–15863
Serum transferrin (mg/dl)200–360190
Ferritin (μg/l)30–400275
Peripheral venous blood gases
 pH7.32–7.427.32
 Bicarbonate (mEq/l)20–2417.5

Reference ranges used at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milano) are for adults who are not pregnant and do not have medical conditions that could affect the result. They may therefore not be appropriate for all patients

Laboratory data upon arrival and at discharge from hospital Reference ranges used at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milano) are for adults who are not pregnant and do not have medical conditions that could affect the result. They may therefore not be appropriate for all patients The patient was admitted to the internal medicine unit for further medical testing and treatment. The gastrointestinal symptoms improved during the first days of hospitalization, as well as renal function. Stool Clostridium difficile toxin test, urine and blood cultures tested negative, while stool culture tested positive for Campylobacter jejuni. During hospitalization, the patient reported frequent presyncopal symptoms. The episodes were characterized by blurry vision, diaphoresis, light-headedness, and in some cases palpitations and chest discomfort. They were mainly triggered by orthostatism, although in some cases could occur in the supine or sitting position, and they were not associated with specific situational triggers. No complete T-LOCs were documented during the hospital stay, but despite the correction of volume depletion and diarrhoea, the patient kept on experiencing presyncope.

Further investigation and differential diagnosis

Dr. Bozzano: continuous telemetric monitoring and serial ECGs showed occasional brief runs of rapid paroxysmal supraventricular tachycardia (PSVT) with spontaneous regression. Morphology was compatible with atrioventricular nodal re-entrant tachycardia, and there was no close correlation with the occurrence of presyncopal symptoms. Pacemaker was tested and it was normally functioning in DDD mode; the recordings showed occasional self-limited tachyarrhythmias with similar PSVT pattern. Transthoracic echocardiography (TTE) revealed a normal cardiac pump function, with preserved left ventricular outflow tract gradients and no signs of aortic stenosis or hypertrophic cardiomyopathy. Dr. Montinaro: once potentially high-risk cardiac disease had been ruled out, patient was examined for other causes of syncope. Orthostatic challenge showed a progressive and sustained BP fall from 140/70 to 80/40 mmHg changing from the supine to the upright position within 3 min of active standing. HR increased from 61 to 71 bpm during the challenge. The fall of BP was able to evoke the presyncopal symptoms, thus defining a classical orthostatic hypotension (OH). Prof. Tobaldini: all antihypertensive agents taken chronically by the patient were stopped, such as the alpha blocker silodosin and beta-blocker bisoprolol, and anticoagulation was interrupted due to the risk of fall. Symptoms were not affected by therapy discontinuation; therefore, further work up was performed due to the high suspicion of primary or secondary autonomic dysfunction. Dr. Carandina: head-up tilt-table testing (TTT) was performed and confirmed a severe OH with associated chronotropic incompetence (Fig. 1). The absence of BP overshoot and of HR increase during the Valsalva manoeuvre were particularly indicative of a neurogenic OH due to autonomic failure. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) revealed a nocturnal “non-dipping” BP pattern, which furtherly supported the diagnosis of autonomic failure.
Fig. 1

Head-up tilt table test results: blood pressure (BP) and heart rate (HR) trends during the phases of tilt test (75°)

Head-up tilt table test results: blood pressure (BP) and heart rate (HR) trends during the phases of tilt test (75°) Dr. Di Fonzo: neurological examination and clinical history were not suggestive of neurodegenerative diseases such as Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure or multiple system atrophy, that may have autonomic failure as part of the clinical picture. Electromyography (EMG) showed a normal nerve conduction and the absence of peripheral neuropathies. CT scan of the brain was normal. Prof. Tobaldini: causes of secondary autonomic failure were searched. Autonomic neuropathy involves postganglionic autonomic nerves and is most commonly caused by diabetes, or uremia, even though OH is rarely the presenting feature. Alcohol consumption has a strong association with dysautonomia too and should always be excluded prior to proceed in differential diagnosis. Medical history, patient’s habits and labs were reviewed and were unconvincing for alcohol-related, uremic, and diabetic aetiologies (Table 1). Other relatively frequent causes of secondary autonomic failure include paraneoplastic neuropathy—which occurs commonly in association with anti-Hu antibodies in patients with small cell lung cancer—autoimmune conditions such as Sjögren syndrome and other collagen vascular disorders, amyloidosis, spinal cord injuries, B12 deficiency, infections (e.g. syphilis, Lyme disease, HIV, Chagas), sarcoidosis, porphyria, and congenital dysautonomia (e.g. Riley-Day syndrome). Laboratory, familial history and clinical findings were inconsistent with the majority of the conditions listed above, while systemic amyloidosis remained a still viable diagnostic hypothesis. Therefore, decision was made to request a fat pad biopsy. Dr. Croci: abdominal fat pad biopsy was carried out at periumbilical site by the plastic surgery service and specimen was processed with Congo red staining and examined using polarizing microscopy. Microscopy was positive for green birefringence under polarized light, compatible with systemic amyloidosis (Fig. 2).
Fig. 2

Histologic examination (Hematoxylin/Eosin, 100×) displays an unremarkable subcutaneous adipose tissue, but featuring the presence of small vessels with subtle thickening of the walls. Congo red stain (inset) showed green birefringence under polarized light, consistent with the clinical suspicion of amyloidosis

Histologic examination (Hematoxylin/Eosin, 100×) displays an unremarkable subcutaneous adipose tissue, but featuring the presence of small vessels with subtle thickening of the walls. Congo red stain (inset) showed green birefringence under polarized light, consistent with the clinical suspicion of amyloidosis Dr. Montinaro: immunohistochemistry was not available in our hospital to identify the type of protein subunit forming fibrils in our patient. Light chain amyloidosis (AL amyloidosis) was reasonably ruled out by excluding an underlying plasma cell proliferative disease—such as multiple myeloma, smoldering myeloma, solitary plasmacytoma or Waldenström macroglobulinemia—as hemoglobin and serum calcium levels were normal, no monoclonal protein was identified at serum protein electrophoresis, Bence-Jones urine protein test was negative and although serum free light chains (FLC) were increased, a normal ratio kappa/lambda was found (Table 2).
Table 2

Serum protein electrophoresis, serum free light chains and urinary protein electrophoresis

VariableReference range, adultsMeasured
Serum protein electrophoresis
 A/G ratio1.30–2.101.14
 Albumin (%)55.8–66.153.2
 Alpha-1 globulins (%)2.9–4.95.7
 Alpha-2 globulins (%)7.1–11.810.9
 Beta-1 globulins (%)4.7–7.26.7
 Beta-2 globulins (%)3.2–6.57.8
 Gamma globulins (%)11.1–18.815.7
 Serum total protein (g/dl)6.40–8.006.30
Serum free light chains
 Chain kappa (mg/liter)3.30–19.4045.05
 Chain lambda (mg/liter)5.71–26.3027.52
 Kappa/lambda ratio0.26–1.651.63
Urinary light chains (Bence Jones protein)AbsentAbsent

Reference ranges used at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milano) are for adults who are not pregnant and do not have medical conditions that could affect the result. They may therefore not be appropriate for all patients

Serum protein electrophoresis, serum free light chains and urinary protein electrophoresis Reference ranges used at the IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milano) are for adults who are not pregnant and do not have medical conditions that could affect the result. They may therefore not be appropriate for all patients Dr. Bozzano: patient was discharged and referred to a highly specialized centre for management and follow-up of systemic amyloidosis. The syncopal episodes were to refer to a reduction in peripheral resistances, due to autonomic failure secondary to amyloidosis.

Discussion

Prof. Tobaldini: OH is a very rare cause of syncope in population < 65 years [1], but its relevance exponentially increases when considering elderly patients (30% of > 75 years with syncope [2]). As seen in our patient, reaching a final diagnosis can be challenging because of the presence of multiple confounding factors that could trigger or mimic syncope, including comorbidities and chronic therapy. When OH is suspected or documented at orthostatic challenge—defined in its “classical” form as a sustained decrease in systolic BP ≥ 20 mmHg, diastolic BP ≥ 10 mmHg, or a sustained decrease in systolic BP to an absolute value < 90 mmHg within 3 min of active standing [3]—the first approach should include discontinuation of potentially aggravating medications and restoration of a normal plasmatic volume prior to further diagnostic evaluation. If symptoms persist, primary or secondary impairment of autonomous nervous system should be taken into account [4]. Dr. Di Fonzo: neurological evaluation to rule out neurodegenerative forms and peripheral neuropathies, EMG, head-up TTT, 24-h ABPM are useful tools to perform differential diagnosis among primary and secondary forms of dysautonomia but require a dedicated setting and should be performed by a specialist trained in autonomic function testing and interpretation [5]. Dr. Montinaro: neurogenic orthostatic hypotension (nOH) can be common in systemic amyloidosis, especially in hereditary transthyretin amyloidosis (h-ATTR) which is the most commonly associated subtype [7]. Amyloidosis is a group of rare protein misfolding disorders, in which insoluble fibrillar proteins, or amyloids, deposit extracellularly and cause end-organ damage. Depending on the precursor protein, clinical manifestations in amyloidosis vary significantly. Extracellular accumulation of abnormally misfolded transthyretin (TTR) leads to ATTR, a multisystemic disorder whose clinical spectrum include sensory-motor neuropathy, cardiac, ocular and less commonly renal involvement [6]. Wild type TTR amyloidosis (wt—ATTR) is typically senile and manifests with a prominent cardiac involvement, while autonomic disfunction is a hallmark of h-ATTR amyloidosis and can include orthostatic hypotension, gastrointestinal dysmotility, erectile disfunction, urinary incontinence, and xerostomia [7]. In a recently published review, it is stated that nOH is a prominent and disabling manifestation of autonomic dysfunction in patients with h-ATTR amyloidosis, affecting an estimated 40–60% of patients and severely impacting their quality of life [8]. Existing links between systemic amyloidosis and autonomic dysfunction are known since long time, although pathophysiological mechanism is still not fully understood. Dr Croci: in our patient, the diagnosis of systemic amyloidosis was made through the biopsy of periumbilical subcutaneous fat. It is an easy, low-cost and low-risk intervention, with a diagnostic sensitivity of 57–85%, which is higher in patients with systemic amyloidosis due to immunoglobulin light chain (primary, or AL), AA protein (secondary), or TTR (senile cardiac or familial amyloid polyneuropathy) deposition, and it is lower in in patients with a single organ involved [9]. Dr. Montinaro: history taking, laboratory findings, urine analyses and FLC assay were used to rule out primary AL ad secondary AA amyloidosis in our patient. Based on peculiar presentation of the disease with nOH alone and no cardiac hypertrophic involvement, h-ATTR amyloidosis was the most likely diagnosis. Dr. Bozzano: getting to a final diagnosis of amyloidosis in patients presenting with nOH alone can be challenging but might significantly improve prognosis and quality of life, since nOH can be treated when it is recognized [8]. Discontinuation of potentially aggravating medications, patient education and non-pharmacologic approaches should be applied first [7]. Droxidopa, a synthetic norepinephrine precursor, has shown efficacy in controlled trials of nOH [10] and is now approved in the US and Asia for patients with h-ATTR amyloidosis [8]. A number of novel drugs directed against amyloid precursor production (e.g. Patisiran, Inotersen) and fibril formation, or promoting TTR tetrameters stabilization (e.g. Tafamidis, Diflunisal) are being investigated and have shown promising results in randomized controlled trials by improving quality-of-life [11-14]. Prof. Tobaldini: finally, in elderly patients with unexplained OH and syncope, it is important to carry out a complete differential diagnosis. This includes ruling out cardiac etiology and major confounding factors, such as iatrogenic hypotension and hypovolemia. It is fundamental to address primary neurodegenerative dysautonomia and other common causes of dysautonomia, such as alcohol consumption and uremia. Been all the above excluded, amyloidosis should always be suspected and investigated.
  11 in total

1.  Subcutaneous adipose tissue biopsy for amyloid protein studies.

Authors:  Per Westermark
Journal:  Methods Mol Biol       Date:  2012

2.  Relation of clinical presentation of syncope to the age of patients.

Authors:  Attilio Del Rosso; Paolo Alboni; Michele Brignole; Carlo Menozzi; Antonio Raviele
Journal:  Am J Cardiol       Date:  2005-09-27       Impact factor: 2.778

3.  2018 ESC Guidelines for the diagnosis and management of syncope.

Authors:  Michele Brignole; Angel Moya; Frederik J de Lange; Jean-Claude Deharo; Perry M Elliott; Alessandra Fanciulli; Artur Fedorowski; Raffaello Furlan; Rose Anne Kenny; Alfonso Martín; Vincent Probst; Matthew J Reed; Ciara P Rice; Richard Sutton; Andrea Ungar; J Gert van Dijk
Journal:  Eur Heart J       Date:  2018-06-01       Impact factor: 29.983

4.  Diagnosis and characteristics of syncope in older patients referred to geriatric departments.

Authors:  Andrea Ungar; Chiara Mussi; Attilio Del Rosso; Gabriele Noro; Pasquale Abete; Loredana Ghirelli; Tommaso Cellai; Annalisa Landi; Gianfranco Salvioli; Franco Rengo; Niccolò Marchionni; Giulio Masotti
Journal:  J Am Geriatr Soc       Date:  2006-10       Impact factor: 5.562

5.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

6.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Authors:  Merrill D Benson; Márcia Waddington-Cruz; John L Berk; Michael Polydefkis; Peter J Dyck; Annabel K Wang; Violaine Planté-Bordeneuve; Fabio A Barroso; Giampaolo Merlini; Laura Obici; Morton Scheinberg; Thomas H Brannagan; William J Litchy; Carol Whelan; Brian M Drachman; David Adams; Stephen B Heitner; Isabel Conceição; Hartmut H Schmidt; Giuseppe Vita; Josep M Campistol; Josep Gamez; Peter D Gorevic; Edward Gane; Amil M Shah; Scott D Solomon; Brett P Monia; Steven G Hughes; T Jesse Kwoh; Bradley W McEvoy; Shiangtung W Jung; Brenda F Baker; Elizabeth J Ackermann; Morie A Gertz; Teresa Coelho
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

7.  Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Marcia Waddington Cruz; Violaine Planté-Bordeneuve; Pierre Lozeron; Ole B Suhr; Josep M Campistol; Isabel Maria Conceição; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Amy Wilson; Donna R Grogan
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

8.  Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management.

Authors:  Jose-Alberto Palma; Alejandra Gonzalez-Duarte; Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2019-08-26       Impact factor: 4.435

Review 9.  Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review.

Authors:  Alejandra Gonzalez-Duarte; Sergio I Valdés-Ferrer; Carlos Cantú-Brito
Journal:  Clin Auton Res       Date:  2019-08-31       Impact factor: 4.435

10.  Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.

Authors:  Horacio Kaufmann; Roy Freeman; Italo Biaggioni; Phillip Low; Simon Pedder; L Arthur Hewitt; Joe Mauney; Michael Feirtag; Christopher J Mathias
Journal:  Neurology       Date:  2014-06-18       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.